Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06193174 · ClinicalTrials.gov registry record · Phase 1
Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)
A Phase 1 study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT06193174 is a Phase 1 study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 1 participants.
The verdict
NCT06193174, a Phase 1 study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to determine how safe and how well-tolerated the experimental study drug, C134 is when re-administered into the brain where the tumor is located.
Interventions
- DRUG C134 Re-Administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-06-21 |
| Est. Completion | 2025-03-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06193174
The ClinicalTrials.gov registry entry for NCT06193174 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which C134 Re-Administration is the first listed.
NCT06193174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06193174 about?
NCT06193174 is a clinical study titled "Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)". The purpose of this study is to determine how safe and how well-tolerated the experimental study drug, C134 is when re-administered into the brain where the tumor is located.
What is the current status of trial NCT06193174?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2024-06-21. Estimated completion is 2025-03-07.
What interventions are being tested in trial NCT06193174?
The interventions under investigation include: C134 Re-Administration (DRUG).
Who is sponsoring clinical trial NCT06193174?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.